Prestige Consumer Healthcare Inc. (NYSE:PBH) Position Boosted by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1,073.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 203,903 shares of the company's stock after purchasing an additional 186,524 shares during the quarter. BNP Paribas Financial Markets owned about 0.41% of Prestige Consumer Healthcare worth $15,923,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Kestra Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $27,000. CIBC Private Wealth Group LLC boosted its holdings in Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after acquiring an additional 152 shares during the last quarter. Headlands Technologies LLC acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at $40,000. Johnson Financial Group Inc. acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at $93,000. Finally, GAMMA Investing LLC boosted its holdings in Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after acquiring an additional 220 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. DA Davidson lifted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. StockNews.com cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Friday, May 9th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Oppenheimer increased their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Finally, Canaccord Genuity Group boosted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $93.33.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This represents a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Stock Up 1.4%

Shares of PBH traded up $1.17 during midday trading on Thursday, reaching $86.57. 156,035 shares of the company were exchanged, compared to its average volume of 297,665. The stock has a 50-day moving average price of $83.16 and a 200-day moving average price of $81.62. The company has a market cap of $4.29 billion, a price-to-earnings ratio of 20.24, a P/E/G ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same quarter in the previous year, the firm posted $1.02 earnings per share. The company's revenue was up 7.0% compared to the same quarter last year. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.